Infacare

In August 2017, Mallinckrodt acquired InfaCare to advance its proprietary therapy for treatment of newborns at risk for developing hyperbilirubinemia (severe jaundice).

Headquarters Plymouth Meeting, PA
Website www.infacare.com​
Pipeline Phase 2B for infantile hyperbilirubinemia